Skip to main content

Crystagen

No sources yet

An index of captured practitioner sources, not a completed evidence summary. Unchecked figures and empty sections are omitted. See the library review status.

Source summary generated November 6, 2026; this date does not indicate completed review.

BioregulatorsAliases: Kristagen, Khavinson immune peptide
Track your own protocol free →

Quotes from three independent practitioners, with their sources. Research context only.

What it is and how it works

From the published literature on Crystagen; the papers are listed at the end. Research summary, not a recommendation.

What it is

Crystagen is a short synthetic peptide from the Saint Petersburg Institute of Bioregulation and Gerontology, the group led by Vladimir Khavinson that has produced a family of two- to four-amino-acid "bioregulator" peptides (Epitalon, Vilon, Thymogen and others). Seller pages describe it as the tripeptide Glu-Asp-Pro aimed at the immune system, but the PubMed abstract found does not state the sequence, so that detail is unconfirmed. Almost all literature comes from the Khavinson group; one Russian-language paper names Crystagen directly, and the other papers below concern the sibling peptides and the group's general reviews, not Crystagen itself. No independent study was found as of 2026-11-06.

How it works

The group proposes that very short peptides can enter the cell nucleus, interact with DNA and histone proteins (the spools DNA winds around) and change which genes are read, a claim set out in their own systematic review and not independently confirmed. In the one paper naming Crystagen, it activated B cells (the antibody-making white blood cells) in the spleen during ageing but, unlike two sibling peptides, did not trigger renewal of spleen cells. In mouse cell studies, related Khavinson peptides altered thymocyte (developing immune cell) growth responses and turned on the interleukin-2 gene in spleen cells, with potency differing from peptide to peptide.

What it has been studied for

  • Immune function in the ageing spleen (Crystagen, Russian-language laboratory study)
  • Immune-cell responses to related short peptides (mouse cells)
  • Peptide regulation of gene expression and ageing (group reviews)

Strength of the evidence

Animal and lab studiesThe only paper naming Crystagen is a laboratory study from the developing group, and no human trial or independent replication was found.

What the literature reports on safety

No safety data in people were found. Crystagen is not an FDA-approved drug and is not named on the FDA compounding-substances page (content current as of 2026-04-22). Because the evidence comes almost entirely from one research institute, the claims should be read as preliminary and unreplicated.

Key papers

  1. Peptide Regulation of Gene Expression: A Systematic Review. (opens in a new tab)

    Review · Khavinson VK, Popovich IG, et al. · Molecules (2021) · PMID 34834147

    The Khavinson group reviewed evidence that short peptides of two to seven amino acids can enter the nucleus, bind DNA and histones and regulate gene expression and DNA methylation.

  2. Molecular aspects of immunoprotective activity of peptides in spleen during the ageing process. (opens in a new tab)

    Animal study · Chervyakova NA, Linkova NS, et al. · Advances in Gerontology (2014) · PMID 28976144

    Reported that Crystagen activated B cells in the spleen during ageing but, unlike Vilon and Thymogen, did not cause cell renewal in the spleen (the English abstract does not name the species).

  3. Effects of short peptides on thymocyte blast transformation and signal transduction along the sphingomyelin pathway. (opens in a new tab)

    Lab (in vitro) · Khavinson VKh, Rybakina EG, et al. · Bulletin of Experimental Biology and Medicine (2002) · PMID 12420072

    In mouse thymocytes, the sibling peptide Vilon had the strongest growth-promoting effect, Epitalon a weaker one and Cortagen none, showing the peptides differ in activity.

  4. In vitro effect of short peptides on expression of interleukin-2 gene in splenocytes. (opens in a new tab)

    Lab (in vitro) · Kazakova TB, Barabanova SV, et al. · Bulletin of Experimental Biology and Medicine (2002) · PMID 12447482

    Vilon, Epitalon and Cortagen each turned on interleukin-2 messenger RNA in mouse spleen cells, with the strength depending on the peptide, concentration and time.

Sources checked: PubMed (E-utilities abstracts for every PMID), FDA compounding-substances page (current as of 2026-04-22), seller reference pages (sequence and positioning only, not used as evidence), written 2026-11-06.

No sources yet

None of the three teachers' sources we have indexed discuss Crystagen yet. This page will fill in as sources are added.

Deeper guided audio lives on What Am I Appreciating Now (leaves this site, opens in a new tab). What Am I Appreciating Now is a separate site run by the same operator; it sells meditation and hypnosis sessions.

Disclaimer: for research purposes only

All content on this page is for research and educational purposes only and is not intended as medical advice. Always consult a qualified healthcare provider before starting any peptide or hormone protocol. You take responsibility for your own protocol.If your path includes peptides, you buy them yourself from an independent licensed provider through a member co-op; we take nothing. How independent access works.

Crystagen — Hunter, Taylor, Bachmeyer | Reset Biology